Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies

Simona Caltagirone, Marina Ruggeri, Simona Aschero, Milena Gilestro, Daniela Oddolo, Francesca Gay, Sara Bringhen, Caterina Musolino, Luca Baldini, Pellegrino Musto, Maria T. Petrucci, Gianluca Gaidano, Roberto Passera, Benedetto Bruno, Antonio Palumbo, Mario Boccadoro, Paola Omedè

Research output: Contribution to journalArticlepeer-review


Multiple myeloma is a plasma cell disorder characterized by malignant plasma cell infiltration in the bone marrow, serum and/or urine monoclonal protein and organ damage. The aim of this study was to investigate the impact of chromosome 1 abnormalities in a group of elderly patients (>65 years) with newly diagnosed multiple myeloma enrolled in the GIMEMA-MM-03-05 trial and treated with bortezomib, melphalan and prednisone or bortezomib, melphalan, prednisone and thalidomide followed by bortezomib and thalidomide maintenance. We also evaluated the link between chromosome 1 abnormalities and other clinical, genetic and immunophenotypic features by a multivariate logistic regression model. Interphase fluorescence in situ hybridization on immunomagnetically purified plasma cells and bone marrow multiparameter flow cytometry were employed. A multivariate Cox model showed that chromosome 1 abnormalities, age >75 years and a CD19+/CD117 immunophenotype of bone marrow plasma cells were independent risk factors for overall survival in elderly patients with newly diagnosed multiple myeloma. Moreover, a detrimental effect of thalidomide, even when administered in association with bortezomib, was observed in patients with abnormal chromosome 1 as well as in those with 17p deletion, while the benefit of adding thalidomide to the bortezomib-melphalan-prednisone regimen was noted in patients carrying an aggressive CD19+/CD117 bone marrow plasma cell immunophenotype. This trial was registered at www.clinicaltrials. gov as #NCT01063179.

Original languageEnglish
Pages (from-to)1611-1617
Number of pages7
Issue number10
Publication statusPublished - Oct 1 2014

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)


Dive into the research topics of 'Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies'. Together they form a unique fingerprint.

Cite this